Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia

Objective To evaluate the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation(allo-HSCT)in patients with secondary acute myeloid leukemia(sAML).Methods In this multicenter,retrospective clinical study,adult patients aged≥18 years who underwent allo-HSCT for sAML at four centers of the Zhejiang Hematopoietic Stem Cell Transplantation Collaborative Group from January 2014 to November 2022 were included,and the efficacy and prognostic factors of allo-HSCT were analyzed.Results A total of 95 patients were enrolled;66(69.5%)had myelodysplastic syndrome-acute myeloid leukemia(MDS-AML),4(4.2%)had MDS/MPN-AML,and 25(26.3%)had therapy-related AML(tAML).The 3-year CIR,LFS,and overall survival(OS)rates were 18.6%(95%CI 10.2%-27.0%),70.6%(95%CI 60.8%-80.4%),and 73.3%(95%CI 63.9%-82.7%),respectively.